Caris Life Sciences Stock | BioTech | Funding to Date: $465,000,000

Operator of a biotechnology company specializing in cancer treatment agents. The company is a provider of molecular science focused on fulfilling the promise of precision medicine and facilitating a deeper understanding of cancer biology and other complex diseases through a suite of molecular profiling offerings assess DNA, RNA and proteins that reveal the molecular blueprint, enabling physicians and cancer patients to make more precise and personalized treatment decisions.


Management Team
  • David Halbert - Co-Founder, Chairman and Chief Executive Officer
  • David Spetzler Ph.D - President & Chief Scientific Officer
  • Thomas Parker - Chief Financial Officer and Senior Vice President
  • Ginger Appleberry JD - Chief Compliance Officer & Associate General Counsel
  • Ronald Merlino - Senior Vice President & Chief Information Officer
  • Stephanie Thomas - Chief of Staff, Executive Vice President & Office of the CEO
  • Brian Lamon Ph.D - Chief Business Officer & Head of BioPharma Business Development
  • Jim Abraham - Chief Data Officer & Senior Vice President
Board Members
  • Brian Brille JD - Caris Life Sciences
  • Danny Phillips -
  • David Halbert - Caris Life Sciences
  • George Poste Ph.D -
  • Jon Halbert - Caris Life Sciences
  • Jonathan Knowles Ph.D - Caris Life Sciences
  • Laurie Johansen JD - Caris Life Sciences
  • Peter Castleman - J.H. Whitney Capital Partners
  • Vijay Mohan - Sixth Street Specialty Lending

Other companies like Caris Life Sciences in the BioTech sector

Ginkgo Bioworks
Est. Val.: $4.89B
Human Longevity
Est. Val.: $50,396,793
Caribou Biosciences
Est. Val.: $143,800,000
Life Biosciences
Est. Val.: $500,000,000
American Gene Technologies International
Est. Val.: $265,000,000
Mammoth Biosciences
Est. Val.: $145,000,000